STOCK TITAN
  1. Home
  2. Sec-filings
  3. HEPA
  4. [Form 4] Hepion Pharmaceuticals, Inc. Insider Trading Activity

Hepion (NASDAQ: HEPA) COO gets 1.35M options at $0.08, expiring 2036

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Hepion Pharmaceuticals, Inc. (HEPA) reported that Chief Operating Officer and director Appajosyula Sireesh received a grant of stock options for 1,345,500 shares of Common Stock on 2026-08-19. The options have a conversion/exercise price of $0.08 per share, expire on 2036-08-19, and are held directly. According to the vesting terms, 336,375 options vest upon grant and the remaining options vest in equal monthly installments over 6 months from the grant date, leaving Sireesh with 1,345,500 options outstanding following this award.

Positive

  • None.

Negative

  • None.
Insider Appajosyula Sireesh
Role Chief Operating Officer
Type Security Shares Price Value
Grant/Award Stock Options F1 1,345,500 $0.00 $0.00
Holdings After Transaction: Stock Options — 1,345,500 shares (Direct)
Footnotes (1)
  1. F1. 336,375 options vest upon grant and the remaining amount vests in equal amounts monthly over 6 months from date of grant.
Stock options granted 1,345,500 options Grant of stock options to Appajosyula Sireesh on 2026-08-19
Exercise price $0.08 per share Conversion/exercise price for the 1,345,500 stock options
Options vesting upon grant 336,375 options Portion of options that vest immediately upon grant
Remaining vesting period 6 months Remaining options vest in equal monthly amounts over 6 months
Options outstanding after grant 1,345,500 options Total shares following the reported transaction
Option expiration date 2036-08-19 Expiration date of the granted stock options
Stock Options financial
"security_title: "Stock Options""
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
conversion_or_exercise_price financial
"conversion_or_exercise_price": "0.0800""
vest upon grant financial
"336,375 options vest upon grant and the remaining amount vests"
expiration_date financial
"expiration_date": "2036-08-19""

FAQ

What did HEPA COO Appajosyula Sireesh report on this Form 4?
Appajosyula Sireesh reported a grant of 1,345,500 stock options for Hepion Pharmaceuticals, Inc. Common Stock, awarded on 2026-08-19, with an exercise price of $0.08 per share and an expiration date of 2036-08-19, all held as direct ownership.

What are the vesting terms of the new HEPA stock options granted to Sireesh?
The filing states that 336,375 options vest upon grant, and the remaining options vest in equal amounts monthly over 6 months from the grant date. This schedule applies to the 1,345,500 stock options granted to Chief Operating Officer Appajosyula Sireesh.

What is the exercise price of the HEPA options granted to Appajosyula Sireesh?
The options granted to Appajosyula Sireesh have a conversion/exercise price of $0.08 per share of Hepion Pharmaceuticals, Inc. Common Stock. This price applies to all 1,345,500 stock options reported in the Form 4.

When do the newly granted HEPA options to Sireesh expire?
The stock options granted to Appajosyula Sireesh expire on 2036-08-19. The Form 4 indicates an exercise date of 2026-08-19 and an expiration date of 2036-08-19 for these 1,345,500 stock options.

How many HEPA options does Sireesh hold after this reported transaction?
Following this grant, Appajosyula Sireesh holds 1,345,500 stock options related to Hepion Pharmaceuticals, Inc. Common Stock, as indicated by the total shares following the transaction field in the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Appajosyula Sireesh
(Last)(First)(Middle)
C/O HEPION PHARMACEUTICALS, INC.
34 SHREWSBURY AVE., SUITE 1D
(Street)
RED BANK, NEW JERSEY 07701
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Hepion Pharmaceuticals, Inc. [ HEPA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options$0.0808/19/2026A1,345,50008/19/2026(1)08/19/2036Common Stock1,345,500$01,345,500D
Explanation of Responses:
1. 336,375 options vest upon grant and the remaining amount vests in equal amounts monthly over 6 months from date of grant.
/s/ Sireesh Appajosyula08/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR